Abstract | BACKGROUND: We compared the efficacy and safety of azilsartan to those of olmesartan in a prospective, randomized clinical trial. METHODS: RESULTS: Office systolic blood pressure (SBP) in the azilsartan group was significantly decreased after 12 weeks. SBP and diastolic blood pressure (DBP) after 12 weeks in the azilsartan group were significantly lower than those in the olmesartan group. The percentage of patients who reached the target BP at 12 weeks (78%) in the azilsartan group was significantly higher than that at 12 weeks (45%) in the olmesartan group. There were no significant changes in pentraxin-3, high-sensitively C-reactive protein or adiponectin in blood after 12 weeks in either group. Although serum levels of creatinine (Cr) in the azilsartan group significantly increased, these changes were within the respective normal range. CONCLUSION: In conclusion, the ability of azilsartan to reduce BP may be superior to that of prior ARBs with equivalent safety in hypertensive patients with CAD.
|
Authors | Sen Adachi, Shin-Ichiro Miura, Yuhei Shiga, Tadaaki Arimura, Takashi Kuwano, Ken Kitajima, Amane Ike, Makoto Sugihara, Atsushi Iwata, Hiroaki Nishikawa, Natsumi Morito, Keijiro Saku |
Journal | Journal of clinical medicine research
(J Clin Med Res)
Vol. 8
Issue 10
Pg. 743-8
(Oct 2016)
ISSN: 1918-3003 [Print] Canada |
PMID | 27635180
(Publication Type: Journal Article)
|